Angiotensin II Receptor Blocker Inhibits Tumour Necrosis Factor-alpha-induced Cell Damage in Human Renal Proximal Tubular Epithelial Cells
Overview
Authors
Affiliations
Aim: We investigated the effect of angiotensin II (AII) type 1 (AT1) and angiotensin II type 2 (AT2) receptor blockers on tumour necrosis factor alpha (TNF-alpha)-induced cell damage in human renal proximal tubular epithelial cells (RPTEC).
Methods: The lactate dehydrogenase (LDH) and N-acetyl-beta-glucosaminidase (NAG) release into the medium after TNF-alpha treatment in RPTEC were determined using modified commercial procedures. In addition, the levels of caspase 3/7 activity in RPTEC were measured after TNF-alpha treatment with AlphaTau1 or AT2 receptor blockers. Finally we investigated the change of p22phox protein levels after TNF-alpha with AlphaTau1 or AT2 receptor blockers in RPTEC.
Results: Tumour necrosis factor alpha (10(-8) mol/L) significantly increased LDH and NAG release into the medium from RPTEC. AlphaTau1 receptor blockers, olmesartan and valsartan (10(-9)-10(-6) mol/L) showed a significant reduction on TNF-alpha-induced LDH and NAG release in RPTEC. AT2 receptor blocker, PD123319 (10(-7)-10(-5) mol/L) also decreased TNF-alpha-induced LDH and NAG release in RPTEC. Blockade of both AlphaTau1 and AT2 receptor indicated additional reduction on TNF-alpha-induced LDH and NAG release. TNF-alpha (10(-8) mol/L) treatment showed small but significant increases of caspase 3/7 activity in RPTEC, and AT1 and AT2 receptor blockers (10(-8) mol/L) comparably decreased TNF-alpha-induced caspase 3/7 activity. Significant increases of p22phox protein levels were observed in TNF-alpha-treated group in RPTEC. However, only AlphaTau1 (10(-8) mol/L) but not AT2 (10(-5) mol/L) receptor blocker significantly decreased TNF-alpha-induced p22phox protein levels.
Conclusion: The present study demonstrates that TNF-alpha induces renal tubular cell damage in RPTEC and AT1/AT2 receptor blockers showed cytoprotective effects probably via at least partly different mechanism.
Piotrowska A, Chmielewska M, Andrzejewski W, Dziegiel P, Podhorska-Okolow M J Renin Angiotensin Aldosterone Syst. 2020; 21(3):1470320320949850.
PMID: 32962526 PMC: 7649907. DOI: 10.1177/1470320320949850.
Computational Drug Screening Identifies Compounds Targeting Renal Age-associated Molecular Profiles.
Koppelstaetter C, Leierer J, Rudnicki M, Kerschbaum J, Kronbichler A, Melk A Comput Struct Biotechnol J. 2019; 17:843-853.
PMID: 31316728 PMC: 6611921. DOI: 10.1016/j.csbj.2019.06.019.
Li L, Liu H, Hu X, Huang Y, Wang Y, He Y Mol Med Rep. 2018; 17(6):7708-7720.
PMID: 29620197 PMC: 5983972. DOI: 10.3892/mmr.2018.8852.
Azzam Z, Kinaneh S, Bahouth F, Ismael-Badarneh R, Khoury E, Abassi Z Front Immunol. 2017; 8:716.
PMID: 28674538 PMC: 5474564. DOI: 10.3389/fimmu.2017.00716.
Oxidant Mechanisms in Renal Injury and Disease.
Ratliff B, Abdulmahdi W, Pawar R, Wolin M Antioxid Redox Signal. 2016; 25(3):119-46.
PMID: 26906267 PMC: 4948213. DOI: 10.1089/ars.2016.6665.